腫瘍科の価格設定と償還に関する支払側の見解

当レポートは、米国と欧州の支払者の視点に焦点を当て、進化するがん治療薬の保険適用と価格設定の状況を詳細に分析したものです。支払者の意思決定に影響を与える主な検討事項、支払者組織における最近の変化の影響、バイオ医薬品業界との関係のダイナミクスを探求しています。また、バイオシミラーの役割、臨床ガイドラインの影響、業界再編や政策変更が支払者の意思決定に及ぼす潜在的な影響についても検証しています。この包括的な分析は、がん領域の薬価および償還に豊富な経験を持つ専門家へのインタビューに基づいています。

レポートの内容

• 支払者ががん治療薬の保険適用と価格設定を決定する際に考慮すべき点
• 最近の変化は、がん治療薬の保険適用と価格設定に関する支払者の考え方にどのような影響を与えたか
• がん治療薬に関する支払者の意思決定に最も大きな影響を与える要因
• 意思決定プロセスを改善するために、支払者とバイオ医薬品業界はどのように協力できるか
• 今後のがん領域における支払者の意思決定に影響を与える可能性のある問題や動向
• 米国とEUで、がん治療薬の保険適用に対する支払者のアプローチはどのように異なるか

主要企業

This report provides an in-depth analysis of the evolving landscape of oncology drug coverage and pricing, focusing on the perspectives of payers in the US and EU. It explores the key considerations influencing payer decisions, the impact of recent changes within payer organisations and the dynamics of their relationships with the biopharmaceutical industry. Readers will gain insights into the strategies payers employ to manage costs, including the use of innovative payment methods and the challenges posed by rising drug prices. The report also examines the role of biosimilars, the influence of clinical guidelines and the potential effects of industry consolidation and policy changes on payer decision making. This comprehensive analysis is informed by interviews with experts who have extensive experience in oncology pricing and reimbursement.

Key Questions Answered:

• 1. What are the key considerations for payers when making coverage and pricing decisions for oncology drugs?
• 2. How have recent changes influenced payer thinking about oncology drug coverage and pricing?
• 3. What factors most heavily impact changes in payer decision making for oncology drugs?
• 4. How can payers and the biopharmaceutical industry collaborate to improve decision-making processes?
• 5. What issues and trends could influence future payer decision making in oncology?
• 6. How do payers' approaches to oncology drug coverage differ between the US and EU?

Key Companies:

Partial List of Participating Experts:

• Associate Director, Office of Health Economics, UK
• Senior clinical account executive at a leading pharmacy benefit manager, US
• President and CEO, Cooperative Benefits Group
• Specialty pharmacy co-founder and oncology leader at payers in the US
• Senior Healthcare Consultant at ADVI Health and former National Medical Director, Aetna, US
• Independent consultant and experienced managed care executive, based in the US
• Senior Vice President, Specialty, Real Endpoints, US
• Venture Partner at RA Capital Management and former EVP and CMO for Harvard Pilgrim Health Care and Point32Health, a regional not-for-profit health plan in the US

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.